MRK-623

Cat. No.:	HY-123840	
CAS No.:	461449-78-5	но
Molecular Formula:	C ₂₀ H ₁₇ FN ₄ O	
Molecular Weight:	348.37	N
Target:	GABA Receptor	
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	F

Inhibitors

BIOLOGICAL ACT			
Description		MRK-623 (Compound 14k) is an orally active, high-affinity GABA _A receptor agonist, with the K _i values of 0.85 nM, 3.7 nM, 4.0 nM, and 0.53 nM for α1, α2, α3, and α5, respectively. MRK-623 shows anxiolytic effect ^[1] .	
In Vitro	MRK-623 shows efficacy at human GABAA receptor subtypes expressed in L(tk ⁻) cells measured by whole cell patch-clamp electrophysiology ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	MRK-623 (oral gavage; 0.3, 1, and 3 mg/kg; once) shows anxiolytic effects in the rat elevated plus maze assay ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Rat	
	Dosage:	0.3, 1, and 3 mg/kg	
	Administration:	Oral gavage; 0.3, 1, and 3 mg/kg; once	
	Result:	Showed 78% BZ site occupancy at 3 mg/kg, with an $\rm ID_{50}$ of 0.8 mg/kg.	

REFERENCES

[1]. Simon C Goodacre, et al. Imidazo[1,2-a] pyrimidines as functionally selective and orally bioavailable GABA(A) alpha2/alpha3 binding site agonists for the treatment of anxiety disorders. J Med Chem. 2006 Jan 12;49(1):35-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA